Alexion Pharmaceuticals intends to assess its blood disorder drug Ultomiris (ravulizumab-cwvz) to treat adult Covid-19 patients hospitalised with severe pneumonia or acute respiratory distress syndrome (ARDS).
The US Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for the drug in severe Covid-19 indication.
Ultomiris is a long-acting C5 complement inhibitor. The biologic medicine has approvals to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and complement-mediated thrombotic microangiopathy.
Share this article
